

... 14 (July 15 2012)
General Collection
W1 CL672
2012-07-26 06:48:43

Clinical Cancer Research

July 15, 2012 • Volume 18 • Number 14 • Pages 3717-3998



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

*The Journal of Clinical and
Translational Research*

Genome & Co. v. Univ. of Chicago
PGR2019-00002
UNIV. CHICAGO EX. 2018

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

Publishing Information

Clinical Cancer Research

The Journal of Clinical and Translational Research

Print ISSN: 1078-0432 • Online ISSN: 1557-3265

AACR Officers

Frank McCormick, President
Charles L. Sawyers, President-Elect
Judy E. Garber, Past President
William N. Hait, Treasurer
Margaret Foti, Chief Executive Officer

Publications Committee

Michael A. Caligiuri, Chairperson
Christine B. Ambrosone
Andrew J. Barker
Powel H. Brown
Richard M. Caprioli
Arul M. Chinnaiyan
Chi Van Dang
Yves A. De Clerck
Jessica Clague DeHart
Lisa Diller
Levi A. Garraway
E. Peter Guengerich
Ernest T. Hawk
Sandra J. Horning
Nancy E. Hynes
Pasi A. Jänne
Kenneth W. Kinzler
Guillermina Lozano
David R. Parkinson
David Piwnicka-Worms
Christoph Plass
Leona D. Samson
Robert H. Vonderheide
George D. Yancopoulos

Publishing Staff

Publisher

Diane Scott-Lichter

Director, Editorial

Helen Barsky Atkins

Managing Editor

Lori Monteleone

Associate Editor

Jesse Potash

Features Editor

Brianna Gallagher

Editorial Staff

Kristin Dross
Emily Senerth
William J. Siegmann
Cara E. Vandy

Associate Director, Production

Charlene Squibb

Production Staff

David Livewell
Jeremy Rosenberg
Victoria Salvucci

Director, Electronic Publishing

Michael Beveridge

Electronic Publishing Staff

Shira Carroll
Mary Beth Cunney
Diane M. Marinelli

Associate Director, Sales and Marketing

Nicola L. Hill

Assistant Director, Circulation and Fulfillment

Karola Rac

Marketing and Creative Services

Director

Paul Driscoll

Design Staff

Susan Moore

Clinical Cancer Research is published twice a month, one volume per year, by the American Association for Cancer Research, Inc. Periodicals postage paid at Philadelphia, PA, and additional mailing offices. POSTMASTER: Send address changes to *Clinical Cancer Research*, Member Services, AACR, 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106-4404 or E-mail: membership@aacr.org. Copyright 2012 by the American Association for Cancer Research, Inc. Printed on acid free paper in the United States of America.

Scope

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.

Clinical Cancer Research is abstracted and/or indexed in MEDLINE, Index Medicus, Web of Science, Science Citation Index, Current Contents/Clinical Medicine, Chemical Abstracts, and Scopus

Submission of Manuscripts

Online manuscript submission is welcomed at <http://ccr.msubmit.net>. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal's home page at <http://clincancerres.aacrjournals.org>

Page Charges

Accepted manuscripts will be published with the understanding that the author(s) will pay a charge of \$95 per printed page for articles one to six pages in length; \$120 per additional page. Discounted charges are available for members.

Subscription Information

AACR Members. Subscription options are print with online access or online access only. Contact membership@aacr.org or see <http://www.aacr.org> and go to the membership page for further information.

Institutions and Nonmembers. Contacts listed below are for single-site online access only (limited to one library only) and optional print subscriptions.

USA, Canada, and Mexico
Turpin Distribution, The Bleachery, 143 West Street, New Milford, CT 06776; phone 860-350-0041, fax 860-350-0039, e-mail turpinna@turpin-distribution.com.

Japan
Send orders and inquiries to one of the following contacts: e-support@maruzen.co.jp; info@jp.swets.com; japan@ebsco.com; journal@kinokuniya.co.jp; usaco@usaco.co.jp.

Rest of World (excluding above)
Turpin Distribution, Pegasus Drive, Stratton Business Park, Biggleswade, Bedfordshire SG18 8TQ, United Kingdom; phone +44-0-1767-604-957, fax +44-0-1767-604-640, e-mail custserv@turpin-distribution.com.

International subscriptions include cost of surface mail. Expedited mailing is available. Contact Turpin Distribution for rates.

Site Licenses. Send site license (online access open to multiple buildings, locations, remote and proxy) inquiries to sitelicense@aacr.org.

Change of Address. Send change of address notification 60 days in advance and include both old and new addresses. Member subscribers should contact AACR Member Services, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404; e-mail membership@aacr.org. Nonmember subscribers should contact Turpin Distribution, The Bleachery, 143 West Street, New Milford, CT 06776; e-mail turpinna@turpin-distribution.com, or Turpin Distribution, Pegasus Drive, Stratton Business Park, Biggleswade, Bedfordshire SG18 8TQ, United Kingdom; e-mail custserv@turpin-distribution.com.

Claims. Claims for missing issues made within 90 days of the issues publication date will be honored while supplies last. Member subscribers should contact membership@aacr.org, phone 215-440-9300, fax 215-440-9412. Institutions and nonmember subscribers should direct claims to Turpin Distribution at the appropriate address above or by e-mail turpinna@turpin-distribution.com.

Single Issue Sales. Single issues and back stock of the journals may be ordered from the AACR main office by calling 866-423-3965 (toll-free) or 215-440-9300. Price of a single issue is \$60 and includes U.S. surface postage. Orders outside of the U.S. are \$65 and include postage.

Advertising Information

Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009 [Phone: (856) 768-9360; Fax: (856) 753-0064].

Copyright and Permissions

As a not-for-profit organization incorporated in the United States, AACR adheres to U.S. copyright law (PL 94-553), which became effective January 1, 1978. The law stipulates that copyright for works is vested in the author from the moment of creation and remains the property of the author until legally transferred. Authors who wish to publish articles and other material in AACR journals must formally transfer copyright to AACR. The copyright transfer form must be signed by all authors before AACR can proceed with publication.

After a manuscript has been deemed potentially acceptable, all authors on the manuscript will be requested to complete an online copyright transfer agreement through the SmartSubmit system. The AACR journals will not publish a paper unless forms have been properly completed and returned by ALL authors.

To read the complete version of AACR's Copyright and Permissions Policy, please visit <http://clincancerres.aacrjournals.org/site/misc/permissions.xhtml>. This policy includes further information on authors' rights of usage, permission requests from third parties, free access to AACR journals, funding agency requirements, and the National Institutes of Health Public Access Policy.

No responsibility is accepted by the Editors or by AACR, Inc. for the opinions expressed by contributors or for the content of the advertisements.

American Association for Cancer Research

615 Chestnut Street
Philadelphia, PA 19106-4404
Phone: 215-440-9300
Fax: 215-440-9354
E-mail: ccr@aacr.org
Website: www.aacr.org

Highlights of This Issue 3717

SPECIAL FEATURES

CCR Translations

- 3719 | **Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks**
John M.L. Ebos and Roberto Pili
See article p. 3961

CCR Perspectives in Drug Approval

- 3722 | **Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary**
Katherine Thornton, Geoffrey Kim, V. Ellen Maher, Somesh Chattopadhyay, Shenghui Tang, Young Jin Moon, Pengfei Song, Anshu Marathe, Suchitra Balakrishnan, Hao Zhu, Christine Garnett, Qi Liu, Brian Booth, Brenda Gehrke, Robert Dorsam, Leigh Verbois, Debasis Ghosh, Wendy Wilson, John Duan, Haripada Sarker, Sarah Pope Miksinski, Lisa Skarupa, Amna Ibrahim, Robert Justice, Anthony Murgo, and Richard Pazdur

Statistics in Clinical Cancer Research

- 3731 | **Cure Models as a Useful Statistical Tool for Analyzing Survival**
Megan Othus, Bart Barlogie, Michael L. LeBlanc, and John J. Crowley

CCR Drug Updates

- 3737 | **Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target**
Leena Gandhi and Pasi A. Jänne

Molecular Pathways

- 3743 | **Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations**
Jeyanthi Eswaran, Da-Qiang Li, Anil Shah, and Rakesh Kumar

Review

- 3750 | **Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience**
Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, and Stan B. Kaye

HUMAN CANCER BIOLOGY

- 3762 | **Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact**
Mário Henrique M. Barros, Rocio Hassan, and Gerald Niedobitek
- 3772 | **Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma**
Yu Sawada, Motonobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kobayashi, and Yoshiki Tokura
- 3780 | **FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma**
Lisa E.S. Crose, Katherine T. Etheridge, Candy Chen, Brian Belyea, Lindsay J. Talbot, Rex C. Bentley, and Corinne M. Linardie
- 3791 | **Integrative Genomic Analysis Implicates Gain of *PIK3CA* at 3q26 and *MYC* at 8q24 in Chronic Lymphocytic Leukemia**
Jennifer R. Brown, Megan Hanna, Bethany Tesar, Lillian Werner, Nathalie Pochet, John M. Asara, Yaoyu E. Wang, Paola dal Cin, Stacey M. Fernandes, Christina Thompson, Laura MacConaill, Catherine J. Wu, Yves Van de Peer, Mick Correll, Aviv Regev, Donna Neuberg, and Arnold S. Freedman

- 3803 **Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas**
Luigi Scotto, Marianna Kruithof-de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, Jairo Baquero Buitrago, Jennifer Amengual, Michael M. Shen, and Owen A. O'Connor
- 3812 **Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia**
Laura A. Vitale, Li-Zhen He, Lawrence J. Thomas, Jennifer Widger, Jeffrey Weidlick, Andrea Crocker, Thomas O'Neill, James Storey, Martin J. Glennie, Deanna M. Grote, Stephen M. Ansell, Henry Marsh, and Tibor Keler
- 3822 **Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor-Targeted Therapy**
Clare McCourt, Pamela Maxwell, Roberta Mazzucchelli, Rodolfo Montironi, Marina Scarpelli, Manuel Salto-Tellez, Joe M. O'Sullivan, Daniel B. Longley, and David J.J. Waugh
- 3834 **Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity**
Deryk Loo, Ralph F. Alderson, Francine Z. Chen, Ling Huang, Wenjun Zhang, Sergey Gorlatov, Steve Burke, Valentina Ciccarone, Hua Li, Yinhua Yang, Tom Son, Yan Chen, Ann N. Easton, Jonathan C. Li, Jill R. Rillema, Monica Licca, Claudia Fieger, Tony W. Liang, Jennie P. Mather, Scott Koenig, Stanford J. Stewart, Syd Johnson, Ezio Bonvini, and Paul A. Moore
- 3846 **Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response**
Harvey Wong, Edna F. Choo, Bruno Aliche, Xiao Ding, Hank La, Erin McNamara, Frank-Peter Theil, Jay Tibbitts, Lori S. Friedman, Cornelis E.C.A. Hop, and Stephen E. Gould
- 3856 **Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206**
Eric Sanchez, Mingjie Li, Cathy Wang, Cydney M. Nichols, Jennifer Li, Haiming Chen, and James R. Berenson

3868

Brachyury, a Driver of the Epithelial-Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer
Mario Roselli, Romaine I. Fernando, Fiorella Guadagni, Antonella Spila, Jhessica Alessandrini, Raffaele Palmirotta, Leopoldo Costarelli, Mary Litzinger, Duane Hamilton, Bruce Huang, Joanne Tucker, Kwong-Yok Tsang, Jeffrey Schlom, and Claudia Palena

3880

Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression
Shu Feng, Longjiang Shao, Wendong Yu, Paul Gavine, and Michael Ittmann

3889

Resistance to TRAIL Is Mediated by DARPP-32 in Gastric Cancer
Abbes Belkhir, Shoumin Zhu, Zheng Chen, Mohammed Soutto, and Wael El-Rifai

3901

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death *In Vitro* and *In Vivo*
Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, and Deepak Sampath

3912

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Timothy A. Yap, Mike I. Walton, Kyla M. Grimshaw, Robert H. te Poele, Paul D. Eve, Melanie R. Valenti, Alexis K. de Haven Brandon, Vanessa Martins, Anna Zetterlund, Simon P. Heaton, Kathrin Heinzmann, Paul S. Jones, Ruth E. Feltell, Matthias Reule, Steven J. Woodhead, Thomas G. Davies, John F. Lyons, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Neil T. Thompson, and Michelle D. Garrett

3924

Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice
Kinya Inoue, Takuji Torimura, Toru Nakamura, Hideki Iwamoto, Hiroshi Masuda, Mitsuhiro Abe, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano, and Michio Sata

IMAGING, DIAGNOSIS, PROGNOSIS

3934 | **Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma**

Jordan Madic, Sophie Piperno-Neumann, Vincent Servois, Aurore Rampanou, Maud Milder, Bénédicte Trouiller, David Gentien, Stéphanie Saada, Franck Assayag, Aurélie Thuleau, Fariba Nemati, Didier Decaudin, François-Clément Bidard, Laurence Desjardins, Pascale Mariani, Olivier Lantz, and Marc-Henri Stern

3942 | **A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival**

Jason A. Willis, Sara H. Olson, Irene Orlow, Semanti Mukherjee, Robert R. McWilliams, Robert C. Kurtz, and Robert J. Klein

3952 | **Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier**

Sarah E. Kerr, Catherine A. Schnabel, Peggy S. Sullivan, Yi Zhang, Veena Singh, Brittany Carey, Mark G. Erlander, W. Edward Highsmith, Sarah M. Dry, and Elena F. Brachtel

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

3972 | **Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis**

Junjie Wu, Jie Liu, Yuhao Zhou, Jun Ying, Houdong Zou, Shicheng Guo, Lei Wang, Naiqing Zhao, Jianjun Hu, Daru Lu, Li Jin, Qiang Li, and Jiu-Cun Wang

3982 | **Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients**

Moubin Lin, Jian Gu, Cathy Eng, Lee M. Ellis, Michelle A. Hildebrandt, Jie Lin, Maosheng Huang, George A. Calin, Dingzhi Wang, Raymond N. DuBois, Ernest T. Hawk, and Xifeng Wu

3992 | **Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy**

Yu-Yun Shao, Chien-Chung Huang, Shiou-Der Lin, Chih-Hung Hsu, and Ann-Lii Cheng

CANCER THERAPY: CLINICAL

3961 | **Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients**

Arjan W. Griffioen, Laurie A. Mans, Annemarie M.A. de Graaf, Patrycja Nowak-Sliwinska, Céline L.M.M. de Hoog, Trees A.M. de Jong, Florry A. Vyth-Dreese, Judy R. van Beijnum, Axel Bex, and Eric Jonasch
See commentary p. 3719

CORRECTION

3998 | **Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck**

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.